Literature DB >> 31498938

Activation of BDNF/TrkB/Akt pathway is associated with aggressiveness and unfavorable survival in oral squamous cell carcinoma.

Juliana Kern de Moraes1, Vivian Petersen Wagner1, Felipe Paiva Fonseca2, Gleyson Kleber do Amaral-Silva1, Caroline Brunetto de Farias3,4, Emily Ferreira Salles Pilar5, Lauro Gregianin4,6, Rafael Roesler3,4,7, Pablo Agustin Vargas1, Manoela Domingues Martins1,5,8.   

Abstract

OBJECTIVES: To evaluate the expression of brain-derived neurotrophic factor (BDNF), its tyrosine kinase receptor B (TrkB), and two downstream targets of this pathway, Akt and ribosomal protein S6 (RPS6), in normal oral mucosa (NOM), oral leukoplakia (OL), and oral squamous cell carcinoma (OSCC) and correlate this expression with OSCC patients' outcomes, cell senescence, and "stemness" profile.
MATERIALS AND METHODS: Ten cases of NOM, 32 OL, and 72 primary OSCC were included. Immunohistochemical analysis for BDNF, TrkB, p-TrkB, p-Akt, and p-RPS6 was performed. Cell senescence and stemness profile of OSCC were evaluated through p16 and BMI-1 immunohistochemical expression, respectively. The slides were scanned into high-resolution images and quantified through digital analysis.
RESULTS: Oral squamous cell carcinoma presented increased expression of BDNF/TrkB/Akt pathway compared to NOM and OL. OSCC diagnosed in advanced clinical stages presented an upregulation of BDNF and p-TrkB. BDNF and p-Akt were identified as predictors of poor disease-specific survival. The increase in stemness profile was correlated with a decrease in p-TrkB and p-Akt expression.
CONCLUSIONS: BDNF/TrkB/Akt pathway is significantly increased in malignant cells from OSCC. Moreover, BDNF and Akt represent biomarkers capable to predict a poor prognosis of OSCC patients.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. All rights reserved.

Entities:  

Keywords:  biomarker; head and neck cancer; immunohistochemistry; predictive value; prognosis

Mesh:

Substances:

Year:  2019        PMID: 31498938     DOI: 10.1111/odi.13190

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  7 in total

Review 1.  BDNF and its signaling in cancer.

Authors:  Mohammad Malekan; Sasan Salehi Nezamabadi; Elham Samami; Mehdi Mohebalizadeh; Amene Saghazadeh; Nima Rezaei
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-29       Impact factor: 4.322

2.  TrkB-Targeted Therapy for Mucoepidermoid Carcinoma.

Authors:  Vivian P Wagner; Manoela D Martins; Esra Amoura; Virgilio G Zanella; Rafael Roesler; Caroline B de Farias; Colin D Bingle; Pablo A Vargas; Lynne Bingle
Journal:  Biomedicines       Date:  2020-11-24

3.  BDNF Acts as a Prognostic Factor Associated with Tumor-Infiltrating Th2 Cells in Pancreatic Adenocarcinoma.

Authors:  Yanan Zhu; Cangang Zhang; Dongyu Zhao; Wenhua Li; Zhe Zhao; Shukun Yao; Dongyan Zhao
Journal:  Dis Markers       Date:  2021-11-05       Impact factor: 3.434

4.  Nodal Enhances Perineural Invasion in Pancreatic Cancer by Promoting Tumor-Nerve Convergence.

Authors:  Sugang Shen; Qiqi Wang; Xueni Wang; Jiachun Ding; Fan Chen; Ying Xiao; Tao Qin; Weikun Qian; Jiahui Li; Qingyong Ma; Jiguang Ma
Journal:  J Healthc Eng       Date:  2022-01-27       Impact factor: 2.682

Review 5.  Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.

Authors:  Lia Walcher; Ann-Kathrin Kistenmacher; Huizhen Suo; Reni Kitte; Sarah Dluczek; Alexander Strauß; André-René Blaudszun; Tetyana Yevsa; Stephan Fricke; Uta Kossatz-Boehlert
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

6.  TrkB Inhibits the BMP Signaling-Mediated Growth Inhibition of Cancer Cells.

Authors:  Min Soo Kim; Wook Jin
Journal:  Cancers (Basel)       Date:  2020-07-28       Impact factor: 6.639

7.  Resveratrol acts via melanoma-associated antigen A12 (MAGEA12)/protein kinase B (Akt) signaling to inhibit the proliferation of oral squamous cell carcinoma cells.

Authors:  Yu Shang; Yu-Ling Jiang; Li-Jun Ye; Li-Na Chen; Yue Ke
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.